With well-known global pharmaceutical companies Novartis and Roche as well as the world's largest contract manufacturer for the pharmaceutical and biotech industry, Lonza, three world-leading companies from the sector are listed on the Swiss Stock Exchange. These are all part of the issuer base of this exchange and form the basis for a well-diversified peer group whose great attractiveness extends far beyond the borders of Switzerland.
Our Sector Focus, Your Advantage
Life sciences companies listed on the Swiss Stock Exchange benefit from outstanding visibility among investors and the media as well as broad coverage by analysts specialising in this sector. Thanks to comprehensive sector-specific know-how, companies can expect a stable market environment and an attractive valuation. Last year, the sector was in the focus of investors and the media as rarely before, and the trading volumes of biotech companies listed on the Swiss Stock Exchange reached new heights, driven by predominantly positive newsflow. In addition, in a challenging market environment with high market volatility, various companies efficiently raised fresh capital through capital increases to further advance research and finance their product pipelines.
Further information and insights regarding the distinguishing features of the Swiss Stock Exchange as a listing location for companies from this sector as well as a review of a past year of records can be found in the this video by Fabian Gerber, Senior Relationship Manager at the Swiss Stock Exchange, which was broadcast at the event under the title “SIX listed Biotech Stocks in the Spotlight”.